332 related articles for article (PubMed ID: 31901783)
1. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.
Kanbayashi Y; Sakaguchi K; Ishikawa T; Ouchi Y; Nakatsukasa K; Tabuchi Y; Kanehisa F; Hiramatsu M; Takagi R; Yokota I; Katoh N; Taguchi T
Breast; 2020 Feb; 49():219-224. PubMed ID: 31901783
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy.
Tsuyuki S; Yamagami K; Yoshibayashi H; Sugie T; Mizuno Y; Tanaka S; Kato H; Okuno T; Ogura N; Yamashiro H; Takuwa H; Kikawa Y; Hashimoto T; Kato T; Takahara S; Katayama T; Yamauchi A; Inamoto T
Breast; 2019 Oct; 47():22-27. PubMed ID: 31302389
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group.
Tsuyuki S; Senda N; Kanng Y; Yamaguchi A; Yoshibayashi H; Kikawa Y; Katakami N; Kato H; Hashimoto T; Okuno T; Yamauchi A; Inamoto T
Breast Cancer Res Treat; 2016 Nov; 160(1):61-67. PubMed ID: 27620884
[TBL] [Abstract][Full Text] [Related]
4. Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial.
Kanbayashi Y; Sakaguchi K; Ishikawa T; Tabuchi Y; Takagi R; Yokota I; Katoh N; Takayama K; Taguchi T
Med Oncol; 2022 Jul; 39(10):153. PubMed ID: 35852641
[TBL] [Abstract][Full Text] [Related]
5. Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
Shigematsu H; Hirata T; Nishina M; Yasui D; Ozaki S
Support Care Cancer; 2020 Oct; 28(10):5005-5011. PubMed ID: 32036471
[TBL] [Abstract][Full Text] [Related]
6. Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.
Kotani H; Terada M; Mori M; Horisawa N; Sugino K; Kataoka A; Adachi Y; Gondou N; Yoshimura A; Hattori M; Sawaki M; Takahata C; Kobara M; Iwata H
BMC Cancer; 2021 May; 21(1):548. PubMed ID: 33985457
[TBL] [Abstract][Full Text] [Related]
7. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial.
Hanai A; Ishiguro H; Sozu T; Tsuda M; Yano I; Nakagawa T; Imai S; Hamabe Y; Toi M; Arai H; Tsuboyama T
J Natl Cancer Inst; 2018 Feb; 110(2):141-148. PubMed ID: 29924336
[TBL] [Abstract][Full Text] [Related]
8. [Possibility of Prolonging Treatment by Preventing Paclitaxel-Induced Peripheral Neuropathy Using Compression Therapy].
Tsuyuki S; Hamada-Nishimoto M; Kang Y; Katayama T
Gan To Kagaku Ryoho; 2022 Nov; 49(11):1241-1245. PubMed ID: 36412028
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
[TBL] [Abstract][Full Text] [Related]
10. Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer.
Ohno T; Mine T; Yoshioka H; Kosaka M; Matsuda S; De Kerckhove M; De Kerckhove C; Irie J; Inoue K; Haraguchi M; Kitajima M; Shinichiro I; Tokai H; Tanaka T; Izumida R
Anticancer Res; 2014 Aug; 34(8):4213-6. PubMed ID: 25075049
[TBL] [Abstract][Full Text] [Related]
11. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.
Ruddy KJ; Le-Rademacher J; Lacouture ME; Wilkinson M; Onitilo AA; Vander Woude AC; Grosse-Perdekamp MT; Dockter T; Tan AD; Beutler A; Loprinzi CL
Breast; 2019 Dec; 48():89-97. PubMed ID: 31590108
[TBL] [Abstract][Full Text] [Related]
13. A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
Kida K; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Doi T; Oba M; Endo I; Ishikawa T
Breast Cancer; 2024 May; 31(3):409-416. PubMed ID: 38453739
[TBL] [Abstract][Full Text] [Related]
14. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
[TBL] [Abstract][Full Text] [Related]
15. Cold therapy to prevent paclitaxel-induced peripheral neuropathy.
Griffiths C; Kwon N; Beaumont JL; Paice JA
Support Care Cancer; 2018 Oct; 26(10):3461-3469. PubMed ID: 29681015
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
[TBL] [Abstract][Full Text] [Related]
17. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer].
Yamada C; Yonezawa M; Shimizu Y; Taga R; Kashihara H; Tsuji K; Murata T; Yoshino H
Gan To Kagaku Ryoho; 2014 Jan; 41(1):77-81. PubMed ID: 24423956
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
